Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10593024 | Bioorganic & Medicinal Chemistry Letters | 2013 | 8 Pages |
Abstract
A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Tesfaye Biftu, Xiaoxia Qian, Ping Chen, Dennis Feng, Giovanna Scapin, Ying-Duo Gao, Jason Cox, Ranabir Sinha Roy, George Eiermann, Huabing He, Kathy Lyons, Gino Salituro, Sangita Patel, Alexander Petrov, Feng Xu, Shiyao Sherrie Xu, Bei Zhang,